Guided Therapeutics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $590.0K | $60.0K | $117.0K | $0 | $1.0K | $0 |
| Cost of Revenue | $0 | $0 | $133.0K | $25.0K | $38.0K | $0 | $3.0K | $0 |
| Gross Profit | $0 | $0 | $457.0K | $35.0K | $79.0K | $0 | $-2.0K | $0 |
| Gross Margin | — | — | 77.5% | 58.3% | 67.5% | — | -200.0% | — |
| Operating Expenses | ||||||||
| Research & Development | $34.0K | $45.0K | $126.0K | $136.0K | $133.0K | $74.0K | $139.0K | $111.0K |
| SG&A Expense | $423.0K | $451.0K | $1.0M | $362.0K | $658.0K | $267.0K | $323.0K | $374.0K |
| Operating Income | $-478.0K | $-302.0K | $-710.0K | $-485.0K | $-763.0K | $-414.0K | $-533.0K | $-561.0K |
| Operating Margin | — | — | -120.3% | -808.3% | -652.1% | — | -53,300.0% | — |
| Interest Expense | $136.0K | $151.0K | $184.0K | $129.0K | $157.0K | $147.0K | $134.0K | $108.0K |
| Pretax Income | $-605.0K | $-500.0K | $-1.2M | $-742.0K | $-811.0K | $-427.0K | $-652.0K | $-654.0K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-605.0K | $-500.0K | $-1.2M | $-742.0K | $-811.0K | $-427.0K | $-1.1M | $-654.0K |
| Net Margin | — | — | -206.1% | -1,236.7% | -693.2% | — | -105,359.8% | — |
| EPS (Basic) | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.01 |
| EPS (Diluted) | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.01 |
| Shares Outstanding (Basic) | 96.5M | 88.8M | 78.4M | 81.7M | 78.8M | 68.3M | — | 57.0M |
| Shares Outstanding (Diluted) | 96.5M | 88.8M | 78.4M | 81.7M | 78.8M | 68.3M | 57.3M | 57.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |